Scholarlink

Purpose of Review <p>Smell loss is among the most debilitating symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to synthesize current evidence on the smell-restoring efficacy of biologics, focusing on outcomes measured by psychophysical tests.</p> Recent Findings <p>Biologics mark a paradigm shift in the management of refractory CRSwNP, offering targeted, effective and safe treatment options. However, their relative impact on psychophysical smell outcomes remains uncertain. With new biologics emerging and real-world evidence accumulating, a comprehensive evaluation is warranted.</p> Summary <p>This systematic review and meta-analysis included eight RCTs (<i>n</i> = 2,081) and an additional review of 20 cohorts (<i>n</i> = 1,681). Among RCTs, biologic therapy produced a large, pooled effect in psychophysical olfactory outcomes (<i>standardised mean difference</i> (SMD) = 1.00, 95% CI = 0.62–1.38, <i>p</i> &lt; 0.0001). Effects differed between agents; dupilumab and tezepelumab produced the largest improvements (SMDs: 1.53, and 1.25, respectively). Omalizumab and telikibart each yielded modest, but statistically significant improvements (SMDs: 0.56, and 0.71, respectively). Mepolizumab and benralizumab did not show statistically significant effects (SMDs: 0.13, and 0.25, respectively). The cohort studies supported a large effect of dupilumab (SMD = 1.57) but focused almost exclusively on dupilumab (19 out of 20 studies). Tezepelumab and dupilumab appear most effective for smell improvement based on available evidence. Head-to-head trials are warranted to more precisely clarify comparative efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Psychophysical Olfactory Outcomes After Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis

  • 期刊论文

  • 发表日期：

    2026年3月28日

查看全文
  • Christian K. Pedersen,
  • Vibeke Backer,
  • Jens Even Tidemandsen,
  • Simon Høj,
  • Marie Høxbro,
  • Anne-Sophie Homøe,
  • Kasper Aanæs,
  • Christian von Buchwald

摘要

Purpose of Review

Smell loss is among the most debilitating symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to synthesize current evidence on the smell-restoring efficacy of biologics, focusing on outcomes measured by psychophysical tests.

Recent Findings

Biologics mark a paradigm shift in the management of refractory CRSwNP, offering targeted, effective and safe treatment options. However, their relative impact on psychophysical smell outcomes remains uncertain. With new biologics emerging and real-world evidence accumulating, a comprehensive evaluation is warranted.

Summary

This systematic review and meta-analysis included eight RCTs (n = 2,081) and an additional review of 20 cohorts (n = 1,681). Among RCTs, biologic therapy produced a large, pooled effect in psychophysical olfactory outcomes (standardised mean difference (SMD) = 1.00, 95% CI = 0.62–1.38, p < 0.0001). Effects differed between agents; dupilumab and tezepelumab produced the largest improvements (SMDs: 1.53, and 1.25, respectively). Omalizumab and telikibart each yielded modest, but statistically significant improvements (SMDs: 0.56, and 0.71, respectively). Mepolizumab and benralizumab did not show statistically significant effects (SMDs: 0.13, and 0.25, respectively). The cohort studies supported a large effect of dupilumab (SMD = 1.57) but focused almost exclusively on dupilumab (19 out of 20 studies). Tezepelumab and dupilumab appear most effective for smell improvement based on available evidence. Head-to-head trials are warranted to more precisely clarify comparative efficacy.